News

You are here

Novosanis, a spin-off of the University of Antwerp, and DDL Diagnostic Laboratory investigated the detection of human papillomavirus (HPV) in first-void urine.
The European Commission granted a “Seal of Excellence” to Novosanis’ project proposal UROSCREEN on the use of Colli-Pee in cervical screening programs.
The European Commission granted a “Seal of Excellence” to Novosanis’ project proposal UROSCREEN on the use of Colli-Pee in cervical screening programs.
De Europese Commissie kende een “Seal of Excellence” toe aan het projectvoorstel UROSCREEN van Novosanis, gericht op het gebruik van Colli-Pee in bevolkingsonderzoek naar...
ANTWERP. POWERED BY CREATIVES. unites award-winning designers during their annual exposition . Novosanis and Voxdale were invited to showcase their innovative health care designs: Colli-Pee...
ANTWERP. POWERED BY CREATIVES. unites award-winning designers during their annual exposition. Novosanis and Voxdale were invited to showcase their innovative designs in regard to health...
As the company keeps growing, we're adding new members to our team. Welcome Piotr & Julie!
As our company has reached a new stage and is generating first commercial sales of its Colli-Pee device, our team needed to grow to meet these new requirements. We proudly present our new...
Novosanis closed a new round of financing. The share capital was increased by a combined cash contribution from current investor Taste Invest and from the Novosanis management team. This...
This weekend Novosanis will be presented at our promotional stand at Urinomics!
Graag nodigen we u uit op het allereerste MedTech Flanders Café, op woensdag 30 september vanaf 18h . LOCATIE Novosanis en Voxdale Bijkhoevelaan 32c 2110 Wijnegem
Novosanis is proud to receive funding from the European Commission (Horizon 2020). The grant allows exploring strategies to successfully launch the Colli-Pee™ device to specifically reach...

Pages